China Scar Treatment Market Analysis and Industry Growth Report, 2025

25 September 2018 -

The China Scar Treatment Market size is expected to reach USD 2.77 billion by 2025 owing to the increasing emphasis on appearance. In the current scenario, all demographic segments of the population lay great importance on enhancing their esthetic appeal. In addition, unsightly scars often cause a huge impact on a person’s quality of life. Scar treatment helps in achieving complete skin rejuvenation, which improves the esthetic appeal of a person.

Rising number of road accidents is considered to be one of the high-impact rendering factors for boosting the demand for scar treatment products. Moreover, increased number of cases of hypertrophic burn scars, wherein the victim’s appearance is distorted, has also resulted in high demand for scar treatment products in China.

China scar treatment market is witnessing considerable technological developments with the introduction of laser therapies. Moreover, plastic and reconstructive surgeries are one of the trending procedures adopted commonly to enhance esthetic appeal. These surgeries help remove various types of scars, which, in turn, rejuvenates the skin.

Browse Details of Report @ https://www.hexaresearch.com/research-report/china-scar-treatment-market

Topical products accounted for the largest market revenue share as they are available as Over-The-Counter (OTC) products, which enables self-care and provides an easy and inexpensive way of scar treatment. With increasing awareness among populations about scar treatment options, the use of topical products has been on the rise.

The laser products are anticipated to witness the highest growth over the projected period as they are an effective and painless approach of scar treatment. Furthermore, technological advancements have significantly fueled the demand for laser treatments to effectively reduce and remove scars. Hence, laser scar removal has evolved as an innovative approach in the field of scar treatment.

In terms of scar type, atrophic scars observed the highest growth owing to the increasing cases of acne scars. A majority of the population deals with acne as a common problem. Moreover, these scars are easily treated with OTC products like creams and gels and the treatment is easy and effective. Thus, increasing the demand for topical products would drive the scar treatment market.

Moreover, hypertrophic and keloid scars are expected to witness a significant growth over the projected period. These scars are a result of injuries and wounds caused mostly due to body piercings, burn injuries, road accidents, and cuts. Growing cases of contracture scars, caused by burn injuries of second and third degree, have resulted in an increased demand for skin treatment products over the past few years.

Hospitals accounted for the largest market share among the end-use segments owing to the availability of various treatment options for scars. Hospitals offer a generalized treatment for majority of the emergency care services and further provide care during the recovery period. Moreover, majority of the population in China prefers hospitals over clinics and OTC medicines for basic care, which is also expected to augment the segment growth.

Furthermore, retail pharmacies/e-commerce segment is expected to witness the highest growth due to the convenience offered by these retail stores.

Hexa Research has segmented the China scar treatment market report based on product, scar type and end use
Segmentation by Product

• Topical Products
• Creams
• Gels
• Silicon sheets
• Others
• Laser Products
• CO2 Laser
• Pulse-dyed Laser
• Others
• Injectables
• Others

Segmentation by Scar Type

• Atrophic scars
• Hypertrophic & Keloid scars
• Contracture scars
• Stretch Marks

Segmentation by End Use

• Hospitals
• Clinics
• Retail pharmacies/E-commerce

Key players analyzed:

• Smith & Nephew PLC
• LUMENIS
• Sonoma Pharmaceuticals, Inc.
• Molnlycke Health Care
• Cynosure, Inc.
• NewMedical Technology, Inc.
• Suneva Medical, Inc.
• Pacific World Corporation
• Perrigo Company PLC 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website: https://www.hexaresearch.com

Global Healthcare BPO Market is Predicted to Witness High CAGR till 2025

The global Healthcare BPO Market size is expected to witness high growth over the forecast period. Increasing need to reduce operational costs is anticipated drive the market. The business process outsourcing (BPO) model has several advantages such as easy availability of skilled labor, low rates, and reduced training costs. Through outsourcing, medical organizations can concentrate on their core competencies and reduce their efforts and investments on support activities. These factors are driving the adoption of BPO in the medical sector.

High prevalence of various diseases has increased workload of medical institutions. Through adoption of outsourcing solutions, these organizations are able to focus on their core activity to maintain quality of service. Outsourcing services assist organizations in different supporting activities such as accounting, medical transcriptions, and patient database maintenance among others. Collaborations with third party healthcare BPO vendors for these activities is a rising industry trend.

Adoption of business strategies such as alignment of major resources towards core competencies is projected to drive the market over the forecast period. Cost cutting through outsourcing business model is anticipated to further augment the market in near future.

Browse Details of Report @ https://www.hexaresearch.com/research-report/healthcare-bpo-market

Costs of medical services have increased significantly over the last few years. Developing countries such as India, Philippines, and China offer skilled labour at low costs. As a result, companies are able to reduce overall cost by delegating work to vendors located in these regions. This factor is anticipated to positively influence the market over the forecast period. Offshore vendors handle activities such as medical billing, accounting, payroll, medical transcription, and coding.

Hospitals in the U.S. maintain a patient database used by insurance organisations for authentication. Database management and analysis are the key activities requiring professionals with adequate interpretation skills. Staff recruitment for such activities turns out to be a costly affair. Hence, hospitals find it easy to partner up with service providers located at distant locations.

However, risks associated with this business model are major restraints hampering overall growth of the healthcare BPO market. Data security is a growing concern owing to high risk of confidential patient data getting misused. Further, most outsourcing establishments are present in Asia Pacific. This makes coordinating in different time zones a challenge for both parties. Moreover, delays in rendering services on account of these factors are the reason why some organisations prefer in-house activities.

A remarkable rise in adoption of advanced technology in the medical and pharmaceutical sectors is anticipated to boost the growth of the global market for healthcare BPO in the forthcoming years. Hospitals have adopted enterprise resource planning (ERP) systems for crowd control and management. Digitization of various supportive medical activities is poised to bode well for demand in near future.

Moreover, government initiatives to reduce service cost is facilitating the need for outsourcing owing to its cost reduction ability. For instance, in 2012, the U.S Supreme Court upheld the main elements of President’s Patient Protection and Affordable Care Act. As per this act, it is mandatory for all American citizens to buy a health coverage. Further, this act is aimed at expanding medical coverage and providing better care along with reduced wasteful spending. The mandate has forced hospitals to focus on their core functions and cut costs by choosing third party sub-contractors for non-core functions.

Pharmaceutical outsourcing, provider outsourcing, and payers outsourcing are the three major applications of healthcare BPO. Pharmaceutical subcontracting is one of the prominent applications in terms of global demand. Provider subcontracting deals with medical coding, billing, Human Resources (HR), and medical coding. Payers segment deals with handling tasks associated with payroll, finance, and accounts.

North America was the leading region in global market on account of highly developed healthcare sector and high in-house operational costs. Pharmaceutical companies in U.S take support of off-shore vendors to focus on research and development.

Asia Pacific is expected to witness significant growth over the forecast period owing to the overall development of medical science coupled with high prevalence of diseases. In addition, Europe is expected to showcase a steady CAGR in near future mainly on account of developed pharmaceutical sector, especially in France and Germany.

Africa and South America are projected to witness a slow expansion owing to sluggish growth of healthcare industry. Moreover, companies from developing economies prefer in-house activities. This factor is anticipated to hinder regional market growth to an extent. Leading countries where vendors have their operational centers are U.S, Mexico, Ireland, France, India, Philippines, China, Vietnam, South Africa and Argentina.

Key players operating in the healthcare BPO market are Cognizant Technologies; Accenture; Wipro Technologies; Tata Consultancy Services; Genpact; WNS; Hinduja Global; Boehringer Ingelheim; Charles River Laboratories; Covance Inc.; Infosys; Lonza Group; Xerox Corporation; HCL Technologies; Exlservice; Medusind; Catalent; GeBBS Healthcare Solutions; and Quintiles, Inc.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-it-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com

Kidney Cancer Drugs market is Driven by Changing Lifestyle of the Global Population

The global Kidney Cancer Drugs Market is expected to grow at a healthy rate during the forecast period. Renal Cell Carcinoma (RCC) is one of the most common types of urologic tumors in adults. It accounts for around 2% of all new cases of tumor in humans. However, clinical removal of the cancerous cells is vital for a total cure from the disease. Until last few decades, surgical removal of kidneys. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

Early diagnosis is vital when it comes to treatment of this disease. Various treatment methods such as immune modulation therapy, Vascular Endothelial Growth Factor (VEGF) inhibitors, and cytokine therapy are utilized to cure the tumor. Additionally, variety of drugs are available for the treatment of diseases like kidney cancer when identified at an early stage. Hence, governments and healthcare organizations are engaging in awareness drives for early detection. This factor is anticipated to bode well for market over the forecast period.

Prevalence of RCC is projected to increase in near future owing to factors such as rising obesity and number of smokers and reduced physical activities due to changing lifestyle. Symptoms of renal cancer are similar to several other kidney disorders, which make it difficult to get detected. This factor also reduces survival rate among patients who are mostly diagnosed with RCC during routine checkups for some other medical conditions.

Browse Details of Report @ https://www.hexaresearch.com/research-report/kidney-cancer-drugs-market

The global market is majorly driven by changing lifestyle of the global population. Predominance of lifestyle influenced diseases is one of the major driving factors. Excessive smoking and alcohol consumption lead to chronic diseases including different types of cancer. This factor is expected to fuel the market for kidney cancer medicine in the forthcoming years. Rising geriatric population prone to chronic diseases is projected to propel demand for these medicines in the years to come.

Preference for these drugs over targeted remedies is anticipated to bode well for growth of the global market over the forecast period. Also, availability of a limited number of approved drugs is one of the factors assisting product demand. Kidney cancer medicines are one of the life protracting treatment options available for patients suffering from advanced stage of metastatic tumor. Furthermore, occurrence of this disease is expected to be higher in developed countries compared to developing regions. This factor is expected to impel demand for these medicines from regions like North America and Europe.

However, high price of branded drugs is projected to hinder overall growth over the forecast period. As a result, generic medicine variants are preferred over their branded counterparts. This factor is anticipated to obstruct market development in the forthcoming years.
Primary branded medicines in the global kidney cancer drugs market include Nexavar (Sorafenib), Inlyta (Axitinib), Avastin (Bevacizumab), Votrient (Pazopanib), Afinitor (Everolimus), Sutent (Sunitinib), Torisel (Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). Sutent was one of the highly demanded medicine types in the past. However, drugs like Votrient are also anticipated to witness substantial demand over the forecast period. At present, most potential drugs are in phase II and III clinical trials. Medicines such as Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib are projected to be commercialized and launched in the years to come.

North America accounted for a prominent market share in the past. High prevalence of kidney cancer and other kidney diseases is the primary growth driver. Additionally, U.S. is the largest market for pharmaceuticals. This factor is anticipated to bode well for the growth of the regional demand for kidney cancer drugs. Asia Pacific is estimated to witness significant growth over the forecast period. Lower cost of drug production, high disease prevalence, and rising awareness among healthcare professionals as well as consumers are projected to drive regional growth in the forthcoming years.

The global market is highly consolidated and displays high competition among key participants. Major pharmaceutical giants in the market include Pfizer Inc.; Bayer Pharma AG; GlaxoSmithKline Plc; Hoffman-La Roche; and Novartis AG. Major companies are capitalizing heavily on research and development and adopting strategies like collaborations, new product launches, business expansions, and innovation to uphold their market share.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Global Antibiotics Market Size and Share 2025

The global Antibiotics Market is expected to foresee significant growth over the forecast period. An antibiotic is a type of antimicrobial used to treat a number of bacterial infections and to slow down the growth of such infections in the body. The global market for antibiotics is witnessing immense growth due to rising investments in research and development activities along with continuous product innovations by major companies. Rising awareness regarding the advantages of antibiotics, particularly in Asia Pacific, is also likely to drive the market. Companies that accounted for most of this increase were based in regions including China, Brazil, India, Russia, and South Africa.

Product consumption varies significantly in different countries as per demand. Two classes of antibiotic drugs including carbapenems and polymyxins have shown increase in the consumption in past few years and this trend is expected to continue even during the forecast period. Over the past few years, numerous companies have been engaged in product manufacturing and about 79% of the global demand is covered by aminoglycoside. There are various products present in the market such as tetracyclines, penicillin, erythromycin, chloramphenicol, and streptomycin. Factors such as rising demand for effective drugs and increasing prevalence of infectious diseases, especially in emerging economies including Middle East, Africa, Latin America, and Asia Pacific, are significant growth drivers for the market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/antibiotics-market

This trend is expected to continue over the next few years. Rising geriatric population is also anticipated to contribute toward the market expansion in the years to come. The main challenge this industry is facing is emergence of drug resistant strains. As in the category of drugs, antibacterial drugs have various unique characteristics, which make them little less profitable and therefore less attractive investments. These drugs are prescribed for short course of time, anywhere from 4 days to 2 weeks as compared to the medications for cholesterol and anti-hypertensive patients, which last for several years or decades. Innovation in technical development is the key opportunity for the market. Numerous companies in this field are continually investing to develop new, advanced products in order to increase their product portfolio.

Major attention is focused on research and development of vital but less profitable antibacterial drug for the companies to sell at a premium price. The demand for antibiotics is rising particularly to treat children with pneumonia and sepsis. In most countries, 20% of the product is used by healthcare facilities and hospitals while 80% is used by the community. These are either purchased directly by the consumers or are prescribed by the healthcare providers.

Antibiotics can be classified into seven major classes namely phenicols, quinolones, macrolides, sulfonamides, aminoglycosides, tetracyclines, and beta lactams. Around half of the market share was claimed by beta lactams class in the past. The second largest class was quinolones. However, the market will experience a decline as a result of the adverse effects on sales due to patent expiries. However, fluoroquinolones/quinolones is expected to foresee a significant demand in the market over the forecast period as they are used in treating a large number of infections.

Some of the key companies operating in the global market are Pfizer, Inc.; Abbott Laboratories; GlaxoSmithKline PLC; Daiichii Sankyo Company Limited; Bayer HealthCare Pharmaceuticals LLC; Astellas Pharma, Inc.; Merck & Company, Inc.; Roche Holding AG; Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc.; GlaxoSmithKline Plc; Pliva d.dd; Toyama Chemica Co. Ltd.; Takeda Pharmaceutical Company. Ltd.; Johnson & Johnson; LG Life Sciences Limited; and Eli Lilly and Co. Pfizer Inc. contributed to the largest share in the past, followed by GlaxoSmithKline PLC and Merck & Company, Inc. With very few patented products available at present, generic manufacturers are leading the global market for antibiotics.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

  

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Sevoflurane, Isoflurane and Desflurane Market to Value USD 1.5 billion by 2022

The Sevoflurane, Isoflurane and Desflurane Market is expected to reach USD 1.5 billion by 2022 in comparison to USD 1.2 billion in 2014. These three chemicals are inhalation agents and have been used by anesthesiologists, nurse anesthetists, and anesthesiology assistants on a consistent basis. They are very strong and cost less, with minimum damage to the ozone layer.  

Market Drivers

One of the primary factors, triggering expansion in the sevoflurane, isoflurane and desflurane market includes cardiovascular and respiratory diseases affecting the geriatric population. Rising cancer, orthopedic, spinal and gastro-intestinal cases have also furthered the market. Cataract surgery is a major contributor to the global market and will need a higher production of these chemicals.

Growing accidents and emergency cases also add income to the inhalation anesthesia market. Universal insurance coverage as well as constant improvements in medical infrastructure also ensure the development of the sevoflurane, isoflurane and desflurane market. These agents are administered to patients prior surgery, making the induction of general anesthesia much simpler.

A major factor hindering the market is the quantity of CO₂ released in the environment,   leading to global warming. Actually, only about 5 percent of the gases are consumed by patients. The rest are released into the atmosphere and make it unhealthy. The most practical solution for this problem is the anesthetic recycling of products used during the administration of general anesthesia.

Browse Details of  Report@ https://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry

Products Overview

Sevoflurane

Sevoflurane is one of the most commonly used volatile anesthetic agents. It is administered to babies and children. Sevoflurane is ideal for patients with asthma or sensitive air passages. But its side-effects include delirium and agitation. It can be given quickly without the use of intravenous instruments.

Sevoflurane would capture over 70% of the worldwide sevoflurane, isoflurane and desflurane market by 2022. The agent is expected to exceed USD 1 billion by the same year. It’s widely utilized for being low-priced and possessing therapeutic benefits.

Isoflurane

Isoflurane is a halogen ether utilized frequently by veterinarians. It is administered intravenously, relaxes the muscles and reduces pain. Isoflurane has also been used for inducing sleepiness for long durations during surgery. It is expected to register a CAGR of about 10% by 2022.

Desflurane

Desflurane is a halogen ether used in general anesthesia. Its effectiveness is one-fifth of isoflurane. Desflurane cannot be administered orally and requires an electrically heated dispenser to distribute the vapor. It is mostly administered to bariatric patients and in cases of surgeries lasting for short durations.

Regional Overview

The United States has a large geriatric population. This has led the region of North America to occupy the biggest share in the worldwide inhalation anesthesia market in 2014. Surgical ambulatory and inpatient procedures are the driving factors of North America.

Asia Pacific will experience the fastest growth by 2022. This is owing to the rise of chronic diseases and need for better health infrastructure in the region. Medical tourism combined with insurance coverage will play a huge role in sustaining the growth of the sevoflurane, isoflurane and desflurane market.

Key Players

The market is currently dominated by AbbVie and Baxter International. However, it can   expect strong competition from manufacturers like Lunan Pharmaceutical Group and Piramal Enterprises.

Piramal Enterprises currently has isoflurane and sevoflurane production underway. It will manufacture generic desflurane by 2016. AbbVie has sevoflurane and isoflurane under production. Baxter International is the only one that manufactures all the three products.

Anesthesia has some unhealthy effects. The recycling companies of Deltasorb Technologies and Anesthetic Gas Reclamation reprocess anesthesia containers and gases from hospital vents. Rising investments by the aforementioned players would also accelerate the sales of the sevoflurane, isoflurane and desflurane market.

Related Reports @

Doxorubicin Market: Doxorubicin market is expected to witness a significant growth in the developed regions due to the multiple incidences of cancer occurrence in these regions. 

Antidiabetic Drug Market : The global antidiabetic drug market is expected to witness substantial growth over the forecast period on account of increasing occurrence of diabetes; both type I and type II and increasing obesity among people across the globe. 

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com 

Key Applications of Neurostimulation Devices Market

A recent study by Hexa Research revealed that limited range of treatment choices relating to medical conditions like epilepsy, Alzheimer’s disease, Parkinson’s disease, migraine headaches, etc. is one of the key drivers of the global Neurostimulation Devices Market. An upcoming application area is the use of neurostimulation devices for therapeutic purposes, commonly referred to as neuromodulation. The neurostimulation devices market is benefitting from technological advancements like the transdermal neuromodulation technology by Neurowave Medical Technologies and MRI safety-enabled devices by Medtronics, Inc.

Rising elderly populace - a high risk demographic for Parkinson’s and Alzheimer’s, is also driving market growth. Accelerated demand for neurostimulation devices in the future years is expected to result from untapped market opportunities in emerging economies of Asia as well as Latin America and the growing number of externally funded clinical programs for development of new products.

Browse Details of Report @ https://www.hexaresearch.com/research-report/neurostimulation-devices-industry/

Hexa Research identifies spinal cord stimulation devices, vagus nerve stimulation devices, gastric electric stimulation devices, deep brain stimulation devices, and sacral nerve stimulation devices to be the key product segments in the neurostimulation devices market. Spinal cord stimulation devices, with a contribution of more than half to the total revenues, were the dominant product segment in 2012.

Pain management proved to be the largest application of neurostimulation devices in 2012 and contributed more than 65% to the total demand that year. This was chiefly due to high incidence of conditions characterized by chronic pain and notable therapeutic effects offered by neurostimulation devices.

While North America contributed around 64% to the total revenues in 2012, Asia Pacific is likely to grow the fastest in future. Fast-developing economies like India and China will result in the Asia Pacific neurostimulation devices market growing at CAGR higher than 16% from 2013 to 2020.

Hexa Research observes that the neurostimulation devices industry exhibits outsourcing of expensive manufacturing activities. This enables industry participants to achieve cost efficiency and better profitability. Key industry players include Boston Scientific Corporation, Cyberonics, Medtronic Inc., and St. Jude Medical.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/

Molecular diagnostic is able to detect cancer at earlier stages

The MolecularDiagnostics Market was valued at over USD 6.40 billion in 2015. It is likely to grow at a CAGR of around 9% during the forecast period (2016-2024).

Increasing prevalence of infectious diseases, cancer, genetic disorders, and other contagious disease are likely to drive the molecular diagnostics industry. Hospital acquired infections and other communicable infections are expected to boost market growth in the coming eight years. Moreover prenatal genetic testing is also expected to increase the adoption of this diagnostics.

Unhealthy lifestyle can further contribute to large number of people getting afflicted with chronic ailments like cardiovascular disorders and diabetes. This with further propel market growth in the coming years. Molecular diagnostics market is divided into products, technologies, applications, test location, and regions.

On the basis of products, the market is split into instruments, reagents, and others. Reagents segment held the largest share in 2015 with revenues exceeding USD 3.5 billion. It is expected to grow at a CAGR surpasing 12%. Instruments segment is expected to show a significant growth in the coming years.

Browse Details of Report @ https://www.hexaresearch.com/research-report/molecular-diagnostics-industry

Technologies consist of polymerase chain reaction (PCR), in-situ hybridization, chips and microarrays, mass spectrometery, DNA sequencing, transportation mediated amplification, and others. PCR held the largest market share of over USD 2.5 billion in 2015. Growth of this segment can be attributed to its high incorporation among the researchers and healthcare professionals. DNA sequencing is likely to show a growth of about 16% CAGR in the coming years.

Applications encompass oncology, pharmacogenomics, infectious diseases, genetic testing, neurological diseases, cardiovascular diseases, and others. Infectious diseases segment was the largest application holding market share exceeding 45% in 2015.

Oncology segment is anticipated to show a CAGR of about 13% till 2024. Rising awareness among people regarding early cancer diagnosis is the key aspect propelling market growth of the segment.

Test location comprises of point of care (PoC), self test or over the counter (OTC), and central laboratories. Central laboratories dominated the market with over 60% shares in 2015. The growth of the central laboratories can be attributed to their large prominence in underdeveloped countries, rising awareness about early detection of diseases, and high procedure volumes.

The PoC is expected to project a lucrative growth with a CAGR of more than 14%. The growth of this segment can be attributed to the increasing demand of bedside patient monitoring and innovative technological devices.

Regions are fragmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa (MEA). America dominated the market with over 40% revenue share. Asia Pacific is likely to exhibit a growth of around 12%CAGR in the coming years.

The key global players of the molecular diagnostics market include Siemens Healthcare GmbH, Novartis AG (Grifols), F. Hoffmann-La Roche Limited, and Johnson & Johnson.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/biotechnology-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/